Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vaccination in Prostate Cancer (VANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02390063
Recruitment Status : Active, not recruiting
First Posted : March 17, 2015
Last Update Posted : January 8, 2019
Sponsor:
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer. A vaccine that could alert the immune system to the presence of cancer cells in the body may enable the immune system to target and kill those cells effectively. This vaccine is intended to work by making the immune system kill cells that have a special protein (called 5T4) that is present on the surface of cancer cells. The vaccine is made up of two recombinant viruses ("ChAdOx1" and "MVA") that have been designed to produce the 5T4 protein and have been modified so that they are weakened and cannot reproduce themselves within the body like normal viruses. Once injected into the body, these viruses make the 5T4 protein and help the body's immune system to learn to target this protein and destroy cancer cells.

This is a first-in-human study to evaluate the safety and immunogenicity of ChAdOx1.5T4-MVA.5T4 vaccination regime. It is evaluated in neo-adjuvant setting in low and intermediate risk localised prostate cancer patients who have either decided to have their prostate removed or are stable on active surveillance.


Condition or disease Intervention/treatment Phase
Prostate Cancer Biological: ChAdOx1.5T4 Biological: MVA.5T4 Drug: Cyclophosphamide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase I Study to Determine the Safety and Immunogenicity of ChAd-MVA Vaccination Compared to MVA Alone With and Without Low Dose Cyclophosphamide in Low and Intermediate Risk Localised Prostate Cancer
Study Start Date : June 2015
Actual Primary Completion Date : May 15, 2018
Estimated Study Completion Date : May 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: CHAMVA standard regime
ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
Biological: ChAdOx1.5T4
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4

Biological: MVA.5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

Experimental: CHAMVA+CTX standard regime
One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
Biological: ChAdOx1.5T4
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4

Biological: MVA.5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

Drug: Cyclophosphamide
Metronomic cyclophosphamide (50mg bd)
Other Name: CTX, CY, Cytoxan

Active Comparator: MVA standard regime
Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
Biological: MVA.5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

Active Comparator: MVA+CTX standard regime
One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
Biological: MVA.5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

Drug: Cyclophosphamide
Metronomic cyclophosphamide (50mg bd)
Other Name: CTX, CY, Cytoxan

Experimental: CHAMVA accelerated regime
ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
Biological: ChAdOx1.5T4
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4

Biological: MVA.5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

Experimental: CHAMVA+CTX accelerated regime
One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
Biological: ChAdOx1.5T4
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4

Biological: MVA.5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

Drug: Cyclophosphamide
Metronomic cyclophosphamide (50mg bd)
Other Name: CTX, CY, Cytoxan

Experimental: CHAMVA accelerated regime AS
ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
Biological: ChAdOx1.5T4
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4

Biological: MVA.5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

Experimental: CHAMVA+CTX accelerated regime AS
One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
Biological: ChAdOx1.5T4
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4

Biological: MVA.5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4

Drug: Cyclophosphamide
Metronomic cyclophosphamide (50mg bd)
Other Name: CTX, CY, Cytoxan




Primary Outcome Measures :
  1. Vaccine safety and immunogenicity [ Time Frame: Up to 52 weeks ]
    Development or increase in anti-5T4 cellular and humoral responses in patients treated with CHAMVA or CHAMVA + CTX


Secondary Outcome Measures :
  1. Cellular and humoral immune response with CHAMVA [ Time Frame: Up to 52 weeks ]
    Development or increase in anti-5T4 cellular and humoral responses in patients treated with the CHAMVA vaccination regimes

  2. Cellular and humoral immune response with MVA [ Time Frame: Up to 52 weeks ]
    Development or increase in anti-5T4 cellular and humoral response in patients treated with the MVA vaccination regimes.

  3. PSA level change secondary to vaccination [ Time Frame: Participants will be followed for the duration of the study, up to 52 weeks ]
    PSA level decrease in patients treated with CHAMVA or MVA vaccination at week 4,8 or 12.

  4. MRI or Gleason score change secondary to vaccination [ Time Frame: Participants will be followed for the duration of the study, up to 52 weeks ]
    Reduction of tumour burden or Gleason score at weeks 4, 8 or 12.

  5. Regulatory T-cell response [ Time Frame: Participants will be followed for the duration of the study, up to 52 weeks ]
    Change in the frequency of regulatory T-cells measured in blood or tumour samples from patients treated with metronomic cyclophosphamide compared to patients not receiving cyclophosphamide



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria(Radical Prostatectomy patients):

  • Males aged 18 years and older
  • Histologically confirmed prostate cancer diagnosed on biopsy within 6 months
  • Clinically localised, low or intermediate risk prostate cancer, i.e.:

    • Gleason score ≤ 7
    • Local tumour stage ≤T2c
    • No evidence of metastases (Nx/N0 and Mx/M0)
    • PSA ≤ 20 ng/ml
  • Scheduled for and considered fit for radical prostatectomy
  • Absence of any indication to perform urgent surgery that would not allow administration of the vaccine during the 12 week period prior to radical prostatectomy
  • No invasive treatment for prostatic disease within the last 2 years
  • Subject is free of clinically apparent/active autoimmune disease (no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, and Insulin Dependent Diabetes Mellitus). Note subjects with Non-Insulin Dependent Diabetes Mellitus can be included.
  • Subject has adequate bone marrow function as defined by an Absolute Lymphocyte Count (ALC) ≥ 500/µL, Absolute Neutrophil Count (ANC) >1200/µL, Platelet Count >100,000/µL.
  • Subject must practice a reliable form of contraception (barrier or vasectomy) while they are being treated with vaccines and another effective method of birth control must also be used by their partner

Inclusion Criteria (Active Surveillance patients)

  • Males aged 18 and older
  • Histologically confirmed prostate cancer diagnosed on biopsy within 6 months
  • Clinically localised, low or intermediate risk prostate cancer, i.e.:

    • Gleason score ≤ 7
    • Local tumour stage ≤T2c
    • No evidence of metastases (Nx/N0 and Mx/M0)
    • PSA ≤ 20 ng/ml
  • Stable disease on Active Surveillance for a minimum of 12 months previously
  • Suitable to remain on Active Surveillance at time of last clinical assessment
  • No invasive treatment for prostatic disease within the last 2 years
  • Subject is free of clinically apparent/active autoimmune disease (no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, and Insulin Dependent Diabetes Mellitus). Note subjects with Non-Insulin Dependent Diabetes Mellitus can be included.
  • Subject has adequate bone marrow function as defined by an Absolute Lymphocyte Count (ALC) ≥ 500/µL, Absolute Neutrophil Count (ANC) >1200/µL, Platelet Count >100,000/µL.
  • Subject must practice a reliable form of contraception (barrier or vasectomy) while they are being treated with vaccines and another effective method of birth control must also be used by their partner

Exclusion Criteria:

  • Diagnosis of any cancer other than prostate cancer within the last 5 years (except basal cell carcinoma)
  • Any suspicion of metastatic cancer
  • Any Gleason grade 5 component in the prostatic biopsies
  • Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  • Seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or HIV
  • Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia, recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed)
  • Platelet count >400,000/μL; Monocytes >80,000/μL; Hemoglobin <11g/dL
  • Known allergy to neomycin
  • History of allergic response to previous vaccinia vaccinations
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products
  • History of hypersensitivity and haemorrhagic cystitis
  • Any history of anaphylaxis
  • Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units per week)
  • History of a serious psychiatric condition or other circumstance s that may be associated with not understanding or complying with the study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02390063


Locations
Layout table for location information
United Kingdom
University of Oxford
Oxford, United Kingdom, OX3 7DQ
Royal Hallamshire Hospital
Sheffield, United Kingdom, S10 2IF
Sponsors and Collaborators
University of Oxford
Investigators
Layout table for investigator information
Study Chair: Freddie Hamdy Oxford University Hospitals NHS Trust

Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT02390063     History of Changes
Other Study ID Numbers: VANCE01
First Posted: March 17, 2015    Key Record Dates
Last Update Posted: January 8, 2019
Last Verified: May 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Cyclophosphamide
Vaccines
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists